Innocare Pharma Sustainability Profile
Innocare Pharma, a leading biopharmaceutical company headquartered in China (CN), is dedicated to advancing innovative therapies in the oncology and autoimmune disease sectors. Founded in 2015, the company has rapidly established itself as a key player in the industry, focusing on the development of novel treatments that address unmet medical needs. With a robust pipeline of targeted therapies and monoclonal antibodies, Innocare Pharma distinguishes itself through its commitment to research and development, leveraging cutting-edge technology to enhance patient outcomes. The company has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position in the global market. As Innocare Pharma continues to expand its operational reach, it remains focused on delivering high-quality, effective solutions that improve the lives of patients worldwide.
DitchCarbon Score
How does Innocare Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innocare Pharma's score of 21 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innocare Pharma's reported carbon emissions
Innocare Pharma, headquartered in China, reported total carbon emissions of approximately 12,134,540 kg CO2e for the year 2023. This total comprises 19,950 kg CO2e from Scope 1 emissions and 12,114,590 kg CO2e from Scope 2 emissions. Notably, there is no reported data for Scope 3 emissions. The company has shown a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The emissions data reflects a significant reliance on electricity and other indirect sources, as evidenced by the substantial Scope 2 figures. In comparison, the previous year, 2022, saw total emissions of approximately 9,835,800 kg CO2e, all from Scope 2, indicating a trend of increasing emissions. The data for 2021 also showed a similar pattern, with total emissions of approximately 9,236,400 kg CO2e, again solely from Scope 2. Innocare Pharma has not inherited emissions data from any parent company, and all reported figures are directly from the organisation itself. The absence of specific reduction targets suggests that while the company acknowledges its emissions, it may still be in the early stages of formalising its climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000 |
| Scope 2 | 2,476,590 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Innocare Pharma's Industry?
How Carbon Intensive is Innocare Pharma's Location?
Innocare Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Innocare Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.